Showing results (191-200 of 379) with videos related to
Sort By:
Pageof 38
Data in Brief|November 25, 2022
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitisLeonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare BRAF MutationsChristian Menzer, Alexander M Menzies, Matteo S Carlino, et al.Journal for Immunotherapy of Cancer|July 24, 2021
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II studySandra P D'Angelo, Celeste Lebbé, Laurent Mortier, et al.Cancer Discovery|November 23, 2013
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanomaEliezer M Van Allen, Nikhil Wagle, Antje Sucker, et al.Journal of Clinical Medicine|July 8, 2020
ECG Changes in Melanoma Patients Undergoing Cancer Therapy-Data From the ECoR RegistryJulia Pohl, Raluca-Ileana Mincu, Simone Maria Mrotzek, et al.British Journal of Pharmacology|June 16, 2026
Refining the treatment of immune checkpoint inhibitor-associated myocarditis: Challenges, innovations and rechallenge considerationsRaluca I Mincu, Lisa Zimmer, Dimitra Vlachopoulou, et al.European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|July 20, 2019
Prognostic factors for pulmonary metastasectomy in malignant melanoma: size mattersJan Viehof, Elisabeth Livingstone, Elena Loscha, et al.European Journal of Cancer (Oxford, England : 1990)|October 16, 2021
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trialLisa Zimmer, Elisabeth Livingstone, Angela Krackhardt, et al.European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsAnne Zaremba, Alexander M M Eggermont, Caroline Robert, et al.Eneurologicalsci|February 19, 2021
Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapySaskia Bolz, Thivyah Ramakrishnan, Michael Fleischer, et al.Pageof 38